Biocon Secures US FDA Approval for Perjeta Biosimilar Pebrilzo
Biocon Ltd 路 Press Release 路 16 Nov 2026, 2:06 pm
Biocon Secures US FDA Approval for Perjeta Biosimilar Pebrilzo The US FDA approved Biocon's Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta for treating HER2-positive breast cancer, marking the company鈥檚 fifth approved oncology biosimilar in the US. Biocon also finalized a global settlement and licensing agreement with Genentech, establishing the earliest licensed US commercial launch date in Q3'CY28. This follows a positive CHMP opinion received in Sep'26 recommending European marketing authorization. Pebrilzo expands Biocon鈥檚 commercial oncology portfolio alongside Ogivri, Jobevne, Fulphila, and Aukelso, with multiple additional biosimilar assets progressing in its pipeline.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
- Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. 路 04 Nov 2026
